Study on Construction of Whole Lifecycle Cohort, Big Data Management and Clinical Prognosis of Cardio-Renal-Metabolic (CKM) Syndrome
Recruiting · NCT07547098 · Observational (researchers observe without assigning treatment) · Lead sponsor: First Affiliated Hospital of Fujian Medical University
View the official record on ClinicalTrials.gov →What this trial is about
This is a single-center observational registry study aiming to establish a structured clinical and multimodal imaging database for cardiovascular-kidney-metabolic (CKM) populations and to support lifecycle follow-up and outcome management. Adult patients aged 18-80 years with cardiovascular, kidney, and/or metabolic diseases or key data for CKM phenotyping will be enrolled at the First Affiliated Hospital of Fujian Medical University. The study integrates retrospective data entry and prospective follow-up, including clinical records, laboratory tests, medications, electrocardiography, echocardiography, vascular function assessment, carotid and abdominal ultrasound, bone density, coronary CTA and post-processing data. The primary outcome is the first occurrence of a cardiorenal composite endpoint. Participants will be followed for up to 5 years through active annual follow-up and passive monthly data updates to support risk stratification, real-world evidence generation, and CKM management pathway optimization.
Who can take part
Inclusion criteria
- Age 18 years or older.
- Inpatient record available at the First Affiliated Hospital of Fujian Medical University with retrievable identifiers for data linkage.
- Cardiovascular disease, kidney disease, metabolic disease, or key examination/laboratory information supporting CKM phenotyping.
- Willingness to participate and provision of written informed consent.
- Ability to complete baseline assessment and follow-up.
- Full civil capacity and ability to understand study information.
Exclusion criteria
- Refusal to provide written informed consent.
- Severe psychiatric disease or cognitive impairment precluding participation.
- End-stage disease with expected survival less than 1 year.
- Long-term absence more than 6 months preventing reliable follow-up.
- Participation in another clinical study that may interfere with endpoint adjudication.
- Missing key fields preventing linkage of examinations, imaging, and outcomes.
Where it is running
1 location listed.
- The First Affiliated Hospital of Fujian Medical University - Fuzhou, Fujian, China